Free Trial
NASDAQ:HRTX

Heron Therapeutics (HRTX) Stock Price, News & Analysis

Heron Therapeutics logo
$2.15 -0.05 (-2.27%)
Closing price 04:00 PM Eastern
Extended Trading
$2.16 +0.01 (+0.47%)
As of 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Heron Therapeutics Stock (NASDAQ:HRTX)

Key Stats

Today's Range
$2.13
$2.23
50-Day Range
$1.72
$2.42
52-Week Range
$1.04
$3.73
Volume
1.46 million shs
Average Volume
2.18 million shs
Market Capitalization
$328.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

Heron Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

HRTX MarketRank™: 

Heron Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 193rd out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Heron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Heron Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Heron Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Heron Therapeutics are expected to grow in the coming year, from ($0.13) to ($0.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Heron Therapeutics is -35.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Heron Therapeutics is -35.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Heron Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    23.82% of the float of Heron Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Heron Therapeutics has a short interest ratio ("days to cover") of 23.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Heron Therapeutics has recently increased by 0.74%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Heron Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Heron Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    23.82% of the float of Heron Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Heron Therapeutics has a short interest ratio ("days to cover") of 23.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Heron Therapeutics has recently increased by 0.74%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Heron Therapeutics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Heron Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    5 people have searched for HRTX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Heron Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.86% of the stock of Heron Therapeutics is held by insiders.

  • Percentage Held by Institutions

    80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Heron Therapeutics' insider trading history.
Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Stock News Headlines

Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
See More Headlines

HRTX Stock Analysis - Frequently Asked Questions

Heron Therapeutics' stock was trading at $1.53 at the beginning of the year. Since then, HRTX stock has increased by 40.5% and is now trading at $2.15.

Heron Therapeutics, Inc. (NASDAQ:HRTX) issued its quarterly earnings data on Tuesday, May, 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The biotechnology company had revenue of $38.90 million for the quarter, compared to the consensus estimate of $37.08 million.
Read the conference call transcript
.

Heron Therapeutics subsidiaries include these companies: Heron Therapeutics B.V..

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/06/2025
Today
7/07/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HRTX
Employees
300
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+127.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.58 million
Pretax Margin
-5.24%

Debt

Sales & Book Value

Annual Sales
$144.29 million
Price / Cash Flow
N/A
Book Value
($0.22) per share
Price / Book
-9.98

Miscellaneous

Free Float
143,624,000
Market Cap
$334.87 million
Optionable
Optionable
Beta
1.18

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:HRTX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners